Harbour BioMed enters into long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates

CAR-T Digest - August 2020

Weekly Digest - January 2026

29 December 2025: Harbour BioMed enters into long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates

Harbour BioMed entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly develop next-generation radionuclide drug conjugates (RDCs), combining antibody discovery expertise with radiopharmaceutical R&D and commercialization capabilities
Harbour BioMed contributes its proprietary Harbour Mice platform, which generates fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. HCAbs are ~50% smaller than IgGs, providing lower immunogenicity, better tissue penetration, and improved specificity and stability for more efficient and safer RDC delivery
RDCs enable targeted radiotherapy by delivering radionuclides directly to tumor lesions via tumor antigen–specific ligands, reducing damage to healthy tissue, overcoming tumor heterogeneity and resistance through bystander effects, and offering theranostic potential by integrating diagnosis and treatment
Founded in 2021, Lannacheng brings an integrated theranostic radiopharmaceutical platform with pharmacokinetic optimization and dual-targeting technologies, covering target validation, radioisotope selection, and linker design, supported by end-to-end capabilities including radioisotope supply and a GMP manufacturing facility under construction in Yantai via its controlling shareholder Dongcheng Biochem
Companies leadership emphasised that the collaboration will deeply integrate Harbour BioMed’s antibody innovation with Lannacheng’s radiopharmaceutical strengths to accelerate the development of more precise, effective, and safer cancer therapies, aiming to bring new treatment options to patients worldwide